Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States

INTRODUCTION: Imatinib is standard therapy for patients with chronic myeloid leukemia (CML). In February 2016, a generic formulation entered the US market. Physicians and patients are frequently concerned about whether switching from original to generic drugs may affect the efficacy and/or safety. M...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cancer Med
Main Authors: Abou Dalle, Iman, Kantarjian, Hagop, Burger, Jan, Estrov, Zeev, Ohanian, Maro, Verstovsek, Srdan, Ravandi, Farhad, Borthakur, Gautam, Garcia‐Manero, Guillermo, Jabbour, Elias, Cortes, Jorge
格式: Artigo
語言:Inglês
出版: John Wiley and Sons Inc. 2019
主題:
Clinical Cancer Research
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6825993/
https://ncbi.nlm.nih.gov/pubmed/31502383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2545
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍